FDA Delays Blenrep Decision, Challenging GSK's Multiple Myeloma Comeback Plans on July 24, 2025 Blenrep Deferred Multiple Myeloma Neoplasms Ocular Toxicity PDUFA regulatory hurdles SmithKline Beecham United States Food and Drug Administration +
FDA Advisory Panel Rejects GSK's Blenrep in New Combinations Over Safety, Efficacy Concerns on July 18, 2025 Advisory Panel Blenrep concerns DREAMM Drug Approval Multiple Myeloma Ocular Toxicity Refractory Plasma Cell Myeloma Relapsing course Safety SmithKline Beecham trials United States Food and Drug Administration +